China's FDA says reports that 83% of trials have fabricated results are incorrect, but the numbers suggest the country still has a big data-integrity…

Daiichi Sankyo's ambition to build a pipeline of new oncology drugs may have just taken another big hit.

Celltrion has new data in hand from a Phase III trial of its Rituxan biosimilar CT-P10, putting it in pole position to grab a piece of the brand's $7.39…

Novartis will shutter two Asian research facilities, but says Shanghai's position as third R&D hub alongside Basel and Cambridge is secure.

Sun Pharmaceutical Industries has taken the lead in a fiercely contested race to market with Johnson & Johnson for a new class of psoriasis drug.

Hanmi Pharma gained one big deal with Roche this week but lost another tie-up with Boehringer--and investors didn't like it one bit.

Sun Pharma licensed a home-grown dengue fever vaccine that it hopes will rival Sanofi's Dengvaxia, which was recently delayed in India.

Complicated drug formulations are generally viewed as a barrier to generic competition, but that is not stopping India's Glenmark from placing Celgene…

R&D